🇺🇸 FDA
Patent

US 8969077

Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord

granted A61KA61K31/7088A61K38/17

Quick answer

US patent 8969077 (Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord) held by The Regents of the University of California expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/7088, A61K38/17, A61K38/177, A61K48/00